Providing Comprehensive Solutions for Protein Therapeutics:

Over a Decade of Experience and Innovation in Protein Biomanufacturing


Protein therapeutics, including recombinant proteins, fusion proteins, enzymes, cytokines, and other biologics, are an important part of modern biopharmaceutical development. With growing demand for higher process efficiency, consistent product quality, and scalable manufacturing, developers need reliable solutions across upstream and downstream operations.

LePure Biotech supports protein biomanufacturing with integrated solutions covering cell culture, process development, filtration, purification, formulation, and filling. With more than a decade of bioprocessing experience, our portfolio includes cell culture media, single-use systems, filtration and purification solutions, and formulation and filling support.

By expanding its portfolio and strengthening process integration, LePure Biotech helps customers improve consistency, streamline operations, and scale the development and manufacture of high-quality protein therapeutics.

Contact Us

Protein Therapeutics Process

Upstream Process

LePure Biotech provides products and bioprocessing services for early-stage antibody and protein therapeutics development, including cell line development, media screening, and lab-scale process optimization.

 

Pilot Scale & Commercial Manufacturing

LePure Biotech is operates large-scale cleanroom facilities, including Class C environments with Grade A unidirectional airflow protection, as well as dedicated workshops for single-use system assembly, supporting the pilot-scale and commercial manufacturing of antibody and protein therapeutics.

Partnering in Protein Therapeutics

LePure Biotech is supported by a global team of application and product specialists, who work closely with customers to provide technical expertise and process focused support.

Our global footprint includes manufacturing sites in Shanghai, Suzhou, and the Greater Bay Area in South China, an R&D center in Boston, USA, and a dedicated business office in Korea.

Discover Our Global Footprint

 

Cell Line

CHO and HEK 293 cell lines sourced from the ECACC cell bank with full traceability and available commercial licensing.

QuaCell CHO-K1Q Cell Line is derived from the ECACC cell bank. Domesticated and screened by QuaCell’s R&D team using patented technology, without genetic modification, it retains core characteristics of CHO-K1 while exhibiting superior tolerance to high lactate, high ammonium, and high osmolality, along with elevated protein expression. Clear source and flexible global commercial license.

WayneLVPro HEK293 Cell Line is derived from the ECACC-HEK293 cell bank. Through domestication and monoclonal screening by QuaCell’s R&D team, a clone with exceptional viral packaging efficiency and transfection performance was selected. Full traceability, globally licensed for commercial use, with exclusive commercial licensing rights within China.

 

 

 

Contact us

By clicking the Submit button, you acknowledge that you have read and agree to the Privacy Policy.

Privacy Policy Consent